CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies
Chimeric antigen receptor (CAR)-T therapy has demonstrated remarkable outcomes read more for B cell malignancies, however, its application for T cell lymphoma, particularly cutaneous T cell lymphoma (CTCL), has been limited.Barriers to effective CAR-T cell therapy in treating CTCL include T cell aplasia in autologous transplants, CAR-T product cont